ANTX - NASDAQ
AN2 Therapeutics, Inc.
$4.28
+3.9%AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
At a Glance
Live SnapshotNo Revenue Data
ANTX has not reported any revenue values in the available annual periods.
AN2 Therapeutics, Inc. Profit Bridge
Profitability Analysis
AN2 Therapeutics, Inc. Income Statement
ANTX • NASDAQ
| AN2 Therapeutics, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
REVENUE | |||||||
GROSS PROFIT | |||||||
(0.0) | (0.0) | (0.0) | (77K) | (0.0) | (0.0) | (0.0) | |
0.0 | 0.0 | 0.0 | -77K | 0.0 | 0.0 | 0.0 | |
OPERATING INCOME | |||||||
(38.1M) | (54.6M) | (69.6M) | (42.2M) | (21.6M) | (7.3M) | (31.1M) | |
(13.3M) | (14.1M) | (14.8M) | (12.8M) | (4.7M) | (1.3M) | (1.7M) | |
(24.8M) | (40.5M) | (54.9M) | (29.5M) | (16.9M) | (6M) | (29.3M) | |
-38.1M | -54.6M | -69.6M | -42.3M | -21.6M | -7.3M | -31.1M | |
PRE-TAX INCOME | |||||||
(0.0) | (0.0) | (0.0) | (514K) | (0.0) | (0.0) | (0.0) | |
2.9M | 5.5M | 0.0 | 837K | 69K | 3K | 0.0 | |
2.9M | 3.2M | 4.9M | 1.3M | 31K | -6.3M | -2.7M | |
-35.2M | -51.3M | -64.7M | -41M | -21.5M | -13.6M | -33.8M | |
NET INCOME | |||||||
-35.2M | -51.3M | -64.7M | -41M | -21.5M | -13.6M | -33.8M |
SEC Filings
ANTX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 11, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 11, 2026 | May 11, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 22, 2026 | April 22, 2026 | 2026 | |
S-3 S-3 N/A | April 09, 2026 | April 09, 2026 | ||
8-K 8-K 2026 N/A | April 09, 2026 | April 09, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 20, 2026 | March 19, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 17, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 17, 2026 | March 17, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 10, 2026 | March 08, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 29, 2026 | January 26, 2026 | 2026 |
Related Guides
Continue your ANTX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.